Rheumatology 2017-08-10T16:23:33+00:00

Rheumatology

Targeted biologics, the recent emergence of innovative new oral therapies and the arrival of biosimilars will continue to fuel monumental shifts in the way patients with auto-immune disorders are managed.

Reports

Click the links below to download report overviews

Reports new KS-02

In-depth analysis of a robust sample of patient journeys detailing the realities of current practice.

RealWorld Dynamix: Biologic/Otezla Switching in PsA US 2017
RealWorld Dynamix: Biologic/JAK Switching in RA US 2017
RealWorld Dynamix: Biologic/JAK Switching in RA EU 2017